ODYSSEY Phase III trials enroll for SAR 236553 treatment of LDL Cholesterol - 22-Jul-2012

Sanofi and Regeneron Pharmaceuticals, Inc. announced that several trials within ODYSSEY, the Phase III clinical program of SAR236553/REGN727, have initiated patient enrollment. SAR236553/REGN727 is a potential first-in-class, subcutaneously administered, fully-human antibody that lowers low-density lipoprotein (LDL) cholesterol by targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), an enzyme which binds LDL receptors, leading to their accelerated degradation and increased LDL-cholesterol (LDL-C) levels.

Related News

Related Cardiology Information

Related Cardiology Drugs

Back to top

Latest News

10 May 2015
25 May 2013
25 May 2013